Fractyl Health(GUTS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates Updated clinical results from German Real-World Registry demonstrate potential for Revita® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted U.S. FDA Breakthrough Device designation for Revita in weight maintenance after discontinuation of GLP-1 based drugs REMAIN-1 pivotal study for Revita in weight maintenance now initiated wit ...